Drug data last refreshed 20h ago · AI intelligence enriched 5d ago
WELLBUTRIN XL is an extended-release oral tablet formulation of bupropion hydrochloride, an atypical antidepressant that increases dopamine and norepinephrine availability in the central nervous system. Approved in 2003, it is indicated for major depressive disorder and seasonal affective disorder. The mechanism differs from SSRIs, making it a valuable option for patients with sexual dysfunction or fatigue.
Product is in LOE-approaching phase with significant but declining market presence; commercial teams will focus on generic transition strategy and retained market share defense.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder
Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
Worked on WELLBUTRIN XL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on WELLBUTRIN XL offers stable, mature product experience in a competitive therapeutic area, but limited growth upside due to approaching LOE and generic saturation. Roles emphasize managed care negotiation, physician relationship maintenance, and patient retention rather than launch excitement or revenue expansion.